KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Equity Ratio for 18 consecutive years, with 0.21 as the latest value for Q1 2026.

  • Quarterly Equity Ratio rose 25.92% to 0.21 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.21 through Mar 2026, up 25.92% year-over-year, with the annual reading at 0.19 for FY2025, 41.97% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.21 at Teva Pharmaceutical Industries, up from 0.19 in the prior quarter.
  • The five-year high for Equity Ratio was 0.22 in Q1 2022, with the low at 0.14 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.18, with a median of 0.18 recorded in 2025.
  • The sharpest move saw Equity Ratio decreased 26.8% in 2024, then surged 41.97% in 2025.
  • Teva Pharmaceutical Industries' Equity Ratio stood at 0.2 in 2022, then decreased by 4.33% to 0.19 in 2023, then decreased by 26.8% to 0.14 in 2024, then surged by 41.97% to 0.19 in 2025, then rose by 5.81% to 0.21 in 2026.
  • Per Business Quant, the three most recent readings for TEVA's Equity Ratio are 0.21 (Q1 2026), 0.19 (Q4 2025), and 0.18 (Q3 2025).